Mixtard 30 Flexpen (Insulin Human)

Insulin human, the active ingredient in Mixtard 30 Flexpen, is an insulin presented as an injectable solution (Flexpen) for subcutaneous use. It mimics the action of endogenous pancreatic insulin, facilitating the uptake of glucose into muscle and adipose tissue while suppressing hepatic glucose production. The product is indicated for the management of hyperglycaemia in both type 1 and type 2 diabetes mellitus.

GNH USA supplies Mixtard 30 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mixtard 30 Flexpen, an insulin formulation that combines rapid‑acting and intermediate‑acting components, is employed in the therapeutic management of diabetes mellitus to regulate blood glucose levels.

- Type 1 diabetes mellitus: supplies both basal and mealtime insulin to mimic physiological insulin patterns, helping patients achieve target glycaemic levels. - Type 2 diabetes mellitus: provides supplemental insulin to overcome insulin resistance and insufficient endogenous secretion, supporting overall glucose control.

Like all insulin preparations, Mixtard 30 Flexpen may be associated with adverse reactions at the injection site and systemic effects.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or activity is increased. - Injection site pain or bruising. - Lipodystrophy: localized fat accumulation or loss at injection sites. - Weight gain: due to improved glucose utilization. - Mild allergic rash or itching. - Peripheral oedema.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms. - Anaphylactic reaction or systemic insulin allergy. - Hypokalemia: low potassium levels. - Acute pancreatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe injection‑site infection.

When using Mixtard 30 Flexpen, clinicians and patients should observe several safety measures.

- Dose individualisation: adjust the dose based on regular blood‑glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients on recognising and treating low glucose episodes. - Renal impairment: monitor closely as reduced renal function may prolong insulin action. - Pregnancy and lactation: use only if the anticipated benefit outweighs potential risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Mixtard 30 Flexpen can interact with other medicines that affect glucose metabolism or mask hypoglycaemia.

Major Interactions (Avoid): - Concurrent sulfonylureas: may precipitate severe hypoglycaemia. - Beta‑blockers: can blunt typical hypoglycaemia warning signs. - Systemic corticosteroids: may increase insulin requirements markedly.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring glucose monitoring. - Thiazide diuretics: can raise blood glucose, necessitating dose adjustment. - Oral contraceptives: may alter insulin needs, warranting closer observation.